117 related articles for article (PubMed ID: 35644011)
1. Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines.
Diamond A; Ayyappan S; Cao S; Tashtish N; Boughan K; Cooper B; Fu P; Caimi PF
Hematol Oncol; 2022 Oct; 40(4):626-636. PubMed ID: 35644011
[TBL] [Abstract][Full Text] [Related]
2. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
3. The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.
Cencini E; Tucci A; Puccini B; Cavallo F; Luminari S; Usai SV; Fabbri A; Pennese E; Marino D; Zilioli VR; Balzarotti M; Petrucci L; Tafuri A; Arcari A; Botto B; Zanni M; Hohaus S; Sartori R; Merli M; Gini G; Al Essa W; Musurca G; Tani M; Nassi L; Daffini R; Mammi C; Marcheselli L; Bocchia M; Spina M; Merli F
Hematol Oncol; 2023 Feb; 41(1):78-87. PubMed ID: 36177902
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of Elderly Patients with Diffuse Large B-cell Lymphoma and the Risk Factors Affecting Cardiotoxicity of Anthracycline.
Zhang L; Jing H; Wang L; Tang S; Wang J
Altern Ther Health Med; 2023 Jul; 29(5):358-363. PubMed ID: 37171952
[TBL] [Abstract][Full Text] [Related]
5. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010.
Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
[TBL] [Abstract][Full Text] [Related]
7. Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma.
Conrad AL; Gundrum JD; McHugh VL; Go RS
J Oncol Pract; 2012 Nov; 8(6):336-40. PubMed ID: 23598842
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.
Davis CC; Cohen JB; Shah KS; Hutcherson DA; Surati MJ; Valla K; Panjic EH; Handler CE; Switchenko JM; Flowers CR
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):270-7. PubMed ID: 25704479
[TBL] [Abstract][Full Text] [Related]
9. Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.
Upshaw JN; Nelson J; Rodday AM; Kumar AJ; Klein AK; Konstam MA; Wong JB; Jaffe IZ; Ky B; Friedberg JW; Maurer M; Kent DM; Parsons SK
JAMA Cardiol; 2023 May; 8(5):453-461. PubMed ID: 36988926
[TBL] [Abstract][Full Text] [Related]
10. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis.
Pugh TJ; Ballonoff A; Rusthoven KE; McCammon R; Kavanagh B; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):845-9. PubMed ID: 19515509
[TBL] [Abstract][Full Text] [Related]
11. An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma.
Toure A; Luan D; Wu Y; Christos PJ; Leonard JP; Martin P
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):e57-e64. PubMed ID: 34446381
[TBL] [Abstract][Full Text] [Related]
12. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L; Federico M; Martelli M; Zinzani PL; Cavanna L; Bellesi G; Merli F; Alterini R; Petrucci MT; Tani M; Liberati AM; Vitolo U; Pavone V; Cuneo A; Chisesib T; Brugiatelli M;
Leuk Lymphoma; 2003 Nov; 44(11):1911-7. PubMed ID: 14738142
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.
Nolasco-Medina D; Reynoso-Noveron N; Mohar-Betancourt A; Aviles-Salas A; García-Perez O; Candelaria M
Biomed Res Int; 2016; 2016():9817606. PubMed ID: 27478844
[TBL] [Abstract][Full Text] [Related]
14. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
15. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
17. Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.
Puckrin R; Ghosh S; Peters A; Stewart D
Leuk Lymphoma; 2022 Mar; 63(3):583-590. PubMed ID: 34672241
[TBL] [Abstract][Full Text] [Related]
18. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; García-Conde J
Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
